Pub Date : 2025-01-01DOI: 10.1016/j.ejcskn.2025.100343
Y.-T. Chang , P. Prompsy , S. Kimeswenger , Y.-C. Tsai , D. Ignatova , O. Pavlova , C. Iselin , L. French , M. Levesque , F. Kuonen , M. Bobrowicz , P. Brunner , S. Pascolo , W. Hoetzenecker , E. Guenova
{"title":"MHC-I upregulation safeguards neoplastic T cells in the skin against NK cell-mediated eradication in mycosis fungoides","authors":"Y.-T. Chang , P. Prompsy , S. Kimeswenger , Y.-C. Tsai , D. Ignatova , O. Pavlova , C. Iselin , L. French , M. Levesque , F. Kuonen , M. Bobrowicz , P. Brunner , S. Pascolo , W. Hoetzenecker , E. Guenova","doi":"10.1016/j.ejcskn.2025.100343","DOIUrl":"10.1016/j.ejcskn.2025.100343","url":null,"abstract":"","PeriodicalId":100396,"journal":{"name":"EJC Skin Cancer","volume":"3 ","pages":"Article 100343"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143746537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/j.ejcskn.2025.100388
G. Borges, R. Descie, M.E. Mauro de Almeida, L. Braga, V. Vazquez
{"title":"Training for aesthetic and body care professionals developed with Design Thinking methodology: An innovative strategy for skin cancer screening","authors":"G. Borges, R. Descie, M.E. Mauro de Almeida, L. Braga, V. Vazquez","doi":"10.1016/j.ejcskn.2025.100388","DOIUrl":"10.1016/j.ejcskn.2025.100388","url":null,"abstract":"","PeriodicalId":100396,"journal":{"name":"EJC Skin Cancer","volume":"3 ","pages":"Article 100388"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143746822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/j.ejcskn.2025.100281
M. Jevric , I. Salatic , D. Brasanac , K. Griewank , A. Hauschild , D. Schadendorf , M. Stojanovic Milosavljevic , J. Filipovic , M. Dencic-Fekete , V. Sondak , M. Zegarac , L. Kandolf
Congenital melanoma is a very rare condition defined as a melanoma recognized at or shortly after birth. It may arise de novo or from transplacental metastasis of maternal melanoma. In this case report, de novo primary congenital melanoma presented during the first four months of life, and was diagnosed by histopathological, immunohistochemical, FISH and genetic analysis. Re-excision and sentinel lymph node biopsy was performed, which revealed a micrometastasis in the sentinel lymph node. No adjuvant treatment was provided. There were no signs of relapse with 15 months postoperative follow-up.
{"title":"Neonatal melanoma with lymph node metastasis","authors":"M. Jevric , I. Salatic , D. Brasanac , K. Griewank , A. Hauschild , D. Schadendorf , M. Stojanovic Milosavljevic , J. Filipovic , M. Dencic-Fekete , V. Sondak , M. Zegarac , L. Kandolf","doi":"10.1016/j.ejcskn.2025.100281","DOIUrl":"10.1016/j.ejcskn.2025.100281","url":null,"abstract":"<div><div>Congenital melanoma is a very rare condition defined as a melanoma recognized at or shortly after birth. It may arise de novo or from transplacental metastasis of maternal melanoma. In this case report, de novo primary congenital melanoma presented during the first four months of life, and was diagnosed by histopathological, immunohistochemical, FISH and genetic analysis. Re-excision and sentinel lymph node biopsy was performed, which revealed a micrometastasis in the sentinel lymph node. No adjuvant treatment was provided. There were no signs of relapse with 15 months postoperative follow-up.</div></div>","PeriodicalId":100396,"journal":{"name":"EJC Skin Cancer","volume":"3 ","pages":"Article 100281"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143183163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mycosis fungoides (MF) is the most common form of a rare cutaneous T-cell lymphoma, often present with patches or plaques on the skin and characterized of malignant T cell infiltration. Topical Chlormethine (CL) gel has been approved by EMA for treatment of adult patients with MF. In clinical practice, chlormethine (CL) gel is often combined with other skin-directed or systemic therapies to optimize response and target recalcitrant lesions.
Objective
Increase knowledge, identify and discuss the use of CL gel on MF lesions in clinical practice with the aim of improving patients health-related quality of life (QoL).
Method
in the present study a modified Delphi methodology is used. A panel of 7 experts (the Scientific Board) was selected to identify 22 statements to be voted by the extended panel (28 expert Italian dermatologists or haematologists) and consensus was reached on most of the points discussed.
Results
In case of early stages of the disease, it was stated that although the use of CL gel is recommended in stages IA-IIA. The panel agreed in supporting the tolerability of CL gel in combination with other topical or systemic therapies, paying attention to the type of lesion treated (stage) and emphasizing the fact that it is a very useful treatment for persistent or refractory lesions. It was also stated by the panel that maintenance therapy after a partial response is suggested until complete remission. Finally, the experts unanimously support how CL gel is characterized by speed of action and flexibility in its application and also has safety features in cases of early and advanced lesions, giving to the patient an improvement of Quality of Life.
{"title":"Italian expert opinion on the treatment of mycosis fungoides with chlormethine gel: Results of a Delphi consensus","authors":"Silvia Alberti Violetti , Marco Ardigò , Raffaele Filotico , Pietro Quaglino , Alessandro Pileri , Nicola Pimpinelli , Pierluigi Zinzani","doi":"10.1016/j.ejcskn.2025.100280","DOIUrl":"10.1016/j.ejcskn.2025.100280","url":null,"abstract":"<div><h3>Background</h3><div>Mycosis fungoides (MF) is the most common form of a rare cutaneous T-cell lymphoma, often present with patches or plaques on the skin and characterized of malignant T cell infiltration. Topical Chlormethine (CL) gel has been approved by EMA for treatment of adult patients with MF. In clinical practice, chlormethine (CL) gel is often combined with other skin-directed or systemic therapies to optimize response and target recalcitrant lesions.</div></div><div><h3>Objective</h3><div>Increase knowledge, identify and discuss the use of CL gel on MF lesions in clinical practice with the aim of improving patients health-related quality of life (QoL).</div></div><div><h3>Method</h3><div>in the present study a modified Delphi methodology is used. A panel of 7 experts (the Scientific Board) was selected to identify 22 statements to be voted by the extended panel (28 expert Italian dermatologists or haematologists) and consensus was reached on most of the points discussed.</div></div><div><h3>Results</h3><div>In case of early stages of the disease, it was stated that although the use of CL gel is recommended in stages IA-IIA. The panel agreed in supporting the tolerability of CL gel in combination with other topical or systemic therapies, paying attention to the type of lesion treated (stage) and emphasizing the fact that it is a very useful treatment for persistent or refractory lesions. It was also stated by the panel that maintenance therapy after a partial response is suggested until complete remission. Finally, the experts unanimously support how CL gel is characterized by speed of action and flexibility in its application and also has safety features in cases of early and advanced lesions, giving to the patient an improvement of Quality of Life.</div></div>","PeriodicalId":100396,"journal":{"name":"EJC Skin Cancer","volume":"3 ","pages":"Article 100280"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143183583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/j.ejcskn.2025.100730
Willem I. Visser , Bianca Tod
{"title":"Melanoma in Skin of Color: Increasing awareness and achieving better disease outcomes – A call to action","authors":"Willem I. Visser , Bianca Tod","doi":"10.1016/j.ejcskn.2025.100730","DOIUrl":"10.1016/j.ejcskn.2025.100730","url":null,"abstract":"","PeriodicalId":100396,"journal":{"name":"EJC Skin Cancer","volume":"3 ","pages":"Article 100730"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143791106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The prognostic value of 18F-FDG PET/CT as part of response monitoring in patients with advanced cutaneous squamous cell carcinoma (cSCC) undergoing anti-PD-1 immune checkpoint inhibitors (ICI) was evaluated in this study.
Methods
Seventy patients underwent 18F-FDG PET/CT before start of treatment and within 4 months of commencement of ICI. Metabolic response evaluation was based on the conventional PERCIST 1.0 criteria and patients were classified as responders (complete or partial) and non-responders. The results of PET/CT were evaluated against progression-free survival (PFS), disease-specific survival (DSS) and overall survival (OS) using the Kaplan- Meier method.
Results
Among the 70 patients, 47 (67 %) were classified as metabolic responders. Compared with non-responders (N = 23,33 %), these patients achieved a significantly prolonged PFS, OS and DSS (p < 0.05). At 24 months, patients attaining a metabolic response had an 89 % PFS, 100 % DSS and 94 % OS compared with non-responders with 11 % PFS, 70 % DSS and 63 % OS at 24 months (p < 0.05). Patients achieving a metabolic response had an improved PFS irrespective of RECIST 1.1 assessment. Patients discontinuing treatment following a metabolic response (N = 13) had durable responses with no progression observed in this group.
Discussion
In patients with cSCC, a positive 18F-FDG PET/CT response assessment within 4 months of ICI commencement, is significantly associated with prolonged PFS, DSS and OS. Response assessment incorporating 18F-FDG PET can assist in early identification of durable responders and better assess for radiological residual disease.
{"title":"The prognostic value of 18F-FDG PET response assessment in patients with advanced cutaneous squamous cell carcinoma undergoing immune checkpoint inhibitors","authors":"Rahul Ladwa , Sarrinder Kenyon , Gillian Jagger , Margaret McGrath , Claire Cuscaden","doi":"10.1016/j.ejcskn.2025.100764","DOIUrl":"10.1016/j.ejcskn.2025.100764","url":null,"abstract":"<div><h3>Introduction</h3><div>The prognostic value of <sup>18</sup>F-FDG PET/CT as part of response monitoring in patients with advanced cutaneous squamous cell carcinoma (cSCC) undergoing anti-PD-1 immune checkpoint inhibitors (ICI) was evaluated in this study.</div></div><div><h3>Methods</h3><div>Seventy patients underwent <sup>18</sup>F-FDG PET/CT before start of treatment and within 4 months of commencement of ICI. Metabolic response evaluation was based on the conventional PERCIST 1.0 criteria and patients were classified as responders (complete or partial) and non-responders. The results of PET/CT were evaluated against progression-free survival (PFS), disease-specific survival (DSS) and overall survival (OS) using the Kaplan- Meier method.</div></div><div><h3>Results</h3><div>Among the 70 patients, 47 (67 %) were classified as metabolic responders. Compared with non-responders (N = 23,33 %), these patients achieved a significantly prolonged PFS, OS and DSS (p < 0.05). At 24 months, patients attaining a metabolic response had an 89 % PFS, 100 % DSS and 94 % OS compared with non-responders with 11 % PFS, 70 % DSS and 63 % OS at 24 months (p < 0.05). Patients achieving a metabolic response had an improved PFS irrespective of RECIST 1.1 assessment. Patients discontinuing treatment following a metabolic response (N = 13) had durable responses with no progression observed in this group.</div></div><div><h3>Discussion</h3><div>In patients with cSCC, a positive <sup>18</sup>F-FDG PET/CT response assessment within 4 months of ICI commencement, is significantly associated with prolonged PFS, DSS and OS. Response assessment incorporating <sup>18</sup>F-FDG PET can assist in early identification of durable responders and better assess for radiological residual disease.</div></div>","PeriodicalId":100396,"journal":{"name":"EJC Skin Cancer","volume":"3 ","pages":"Article 100764"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145424559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/j.ejcskn.2025.100750
Julian Steininger , Christoph G. Radosa , Matthias Meinhardt , Friedegund Meier , Frank Friedrich Gellrich
{"title":"Corrigendum to “Merkel cell carcinoma with leptomeningeal involvement: A complex case report” [EJC Skin Cancer 2 (2024) 100018]","authors":"Julian Steininger , Christoph G. Radosa , Matthias Meinhardt , Friedegund Meier , Frank Friedrich Gellrich","doi":"10.1016/j.ejcskn.2025.100750","DOIUrl":"10.1016/j.ejcskn.2025.100750","url":null,"abstract":"","PeriodicalId":100396,"journal":{"name":"EJC Skin Cancer","volume":"3 ","pages":"Article 100750"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145048273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号